|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||84.89 - 86.09|
|52 Week Range||72.67 - 94.19|
|PE Ratio (TTM)||26.12|
|Forward Dividend & Yield||2.72 (3.18%)|
|1y Target Est||98.06|
Novartis’s (NVS) Gilenya reported sales of $825 .0 million in 4Q17, which is a year-over-year (or YoY) drop of 1.0% on a constant currency basis. The court declared that Gilenya’s formulation patent protecting the drug until 2026 is invalid.
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
Vasant Narasimhan, the 41-year-old chief executive at Novartis AG, is vowing data science and digital technologies will revolutionize the company’s drug-development pipeline.
Greek lawmakers begin discussions Wednesday on the alleged role of former senior government officials in a Novartis AG bribery case, which is part of a drug-overpricing scandal that’s estimated to have ...
Clinical stage biopharma company resTORbio, Inc. (NASDAQ: TORC )'s TORC1 inhibition program uses a protein called serine/threonine kinase that aims to regulate aging and aging-related diseases conditions ...
Novartis: What Are the Major Growth Drivers for 2018? On October 30, 2017, Novartis (NVS) announced its plans to acquire radiopharmaceutical company Advanced Accelerator Applications. On January 22, 2018, Novartis completed the tender offer.
Novartis: What Are the Major Growth Drivers for 2018? Novartis’s (NVS) Promacta reported sales if $255 million in 4Q17, which is a year-over-year (or YoY) rise of 43.0% on a constant currency basis. On January 4, 2018, Novartis announced that the FDA granted breakthrough therapy designation to the combination of Promacta and immunosuppressive therapy.
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / U.S. markets closed Friday with weekly gains in the range of 4 percent to 5 percent. The Dow Jones Industrial Average gained 0.08 percent to close at 25,219.38, ...
Novartis: What Are the Major Growth Drivers for 2018? On March 13, 2017, the FDA announced the approval of the combination regimen of Novartis’s (NVS) Kisqali with an aromatase inhibitor. This regimen is a first-line treatment option for postmenopausal women with hormone receptor-positive (or HR) human epidermal growth factor receptor 2-negative (or HER2) advanced or metastatic breast cancer.
Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).
Source link: http://on.wsj.com/2sFw8k8 Note: Reuters has not verified this story and cannot vouch for its accuracy.
Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.